Humana (HUM) Stock Forecast & Price Target

Humana is expected to have a strong outlook due to its niche in government-sponsored programs, including Medicare, Medicaid, and Tricare, and its diversification into other healthcare services. The company has a solid track record of growth, with a projected 18x multiple of its adjusted EPS of $14.08 for CY27 and expected margin expansion in CY28. The company also has financial cushioning against potential underperformance in CY26, and its management is focused on achieving 3% margin by 2028 and member retention. While there may be risk to CY26 Individual MA margin, Humana has a strong foundation for long-term growth.

Humana is facing headwinds in their Medicare Advantage (MA) segment due to cutbacks in government-sponsored programs and increasing competition, which could pressure margins more than expected. Additionally, their growing healthcare services business may not be able to reduce medical costs as much as expected. HUM is closely monitoring trends and maintaining a conservative approach to IBNR due to a large influx of new members, but it remains to be seen if their guidance for a turnaround in 2026 will be achieved. Non-core asset sales and capital deployment may be necessary to fund strategic acquisitions and boost earnings growth.